# EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

*PRI Rank #5 · Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/rank-5*

| Field | Value |
| --- | --- |
| Rank | #5 |
| 18m citations | 121 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco.2024.42.3_suppl.lba432 |
| Corresponding authors | Riccardo Lencioni |
| Institution | University of Pisa, Italy |

**Ranking page:** [Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026](https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026)

**Paper link:** [10.1200/jco.2024.42.3_suppl.lba432](https://doi.org/10.1200/jco.2024.42.3_suppl.lba432)

## Topics

Hepatocellular carcinoma · Unresectable hepatocellular carcinoma · Transarterial chemoembolization · durvalumab · bevacizumab · Immune checkpoint inhibitor therapy · VEGF inhibition · Progression-free survival · Overall survival · Objective response rate · Time to progression · Barcelona Clinic Liver Cancer (BCLC) staging · embolization-eligible HCC · proinflammatory tumor microenvironment · VEGF signaling pathway · PD-1/PD-L1 inhibitor · Transarterial chemoembolization · drug-eluting bead TACE · Child-Pugh class · Performance status · RECIST 1.1 · blinded independent central review · Phase III clinical trial · Placebo-controlled trial · Treatment-related adverse events · hazard ratio · standard of care · Extrahepatic metastasis · Tumor microenvironment · ICI-based combination therapy

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```